Review Article
Volume 3 Issue 4 - 2016
Osseo Regeneration of the Cranio-Maxillo-Facial and Oro-Dento-Alveolar Complexes Using a Novel Self-Assembling Peptide Nanofibrous Hydrogel Scaffold and Its Composites
Constanza L Jiménez1, Constanza G Melandri2 and Ziyad S Haidar1,3,4*
1BioMAT’X, Facultad de Odontología, Universidad de Los Andes, Santiago de Chile
2Alumna del Postítulo de Periodoncia e Implantología Quirúrgica, Facultad de Odontología, Universidad de Los Andes, Santiago de Chile
3Plan de Mejoramiento Institucional (PMI) en Innovación I+D+i, Universidad de Los Andes, Santiago de Chile
4Centro de Investigación Biomédica, Facultad de Medicina, Universidad de Los Andes, Santiago de Chile
*Corresponding Author: Prof. Dr. Ziyad S Haidar, DDS, Certified Implantology, MSc OMFS, MBA, PhD; Professor and Scientific Director, Facultad de Odontología, Universidad de los Andes, Mons. Álvaro del Portillo 12.455 - Las Condes, Santiago, Chile. Founder and Head of BioMAT’X (Biomaterials, Pharmaceutical Delivery and Cranio-Maxillo-Facial Tissue Engineering Laboratory and Research Group), Biomedical Research Center (CIB), PMI I+D+i, Department for Research, Development and Innovation, Universidad de los Andes, Mons. Álvaro del Portillo 12.455 - Las Condes, Santiago, Chile.
Received: November 10, 2015; Published: January 22, 2016
Citation: Ziyad S Haidar., et al. “Osseo Regeneration of the Cranio-Maxillo-Facial and Oro-Dento-Alveolar Complexes Using a Novel Self-Assembling Peptide Nanofibrous Hydrogel Scaffold and Its Composites”. EC Dental Science 3.4 (2016): 568-579.
Introduction: Craniofacial reconstructive surgery allows the repair and restoration of defected tissues and/or organs, yet, with limitations. Regenerative engineering of complex tissues requires a precisely formulated combination of cells, spatio-temporally released bioactive growth factors, and a specialized scaffold system to provide support. Hence, auto-grafts (current gold standard treatment choice) are associated with numerous disadvantages. Thus, development of new alternative biomaterials for bone regeneration continues to be a hot research topicin Dentistry. Therapeutic transplant of human mesenchymal stem cells into bone defects is an appealing strategy for bone tissue engineering nonetheless, a main challenge for its clinical application relates to the need of adequate scaffolds for cell delivery and support. PuraMatrix™ is a novel and commercially-available self-assembling peptide nanofibrous scaffold with appealing properties for osseo-regeneration. Despite promising results in other medical disciplines, its potential in Dentistry is largely under-investigated. This review provides an up-to-date overview of the use of PuraMatrix™ for cranio-maxillo-facial and oro-dento-alveolar complexes bone regeneration and repair.
Materials and Methods: A structured literature search was performed on PUBMED using the search terms “PuraMatrix” and “Bone”. A total of 29 articles were found, though only studies related to Bone Regeneration are included.
Results: 7 articles dealing with potential use and application of PuraMatrix™ for bone tissue engineering were identified. Briefly, PuraMatrix™ supports the survival, proliferation and migration of osteoblast-like stem cells without interference with their osteogenic differentiation. Stem cells seeded in PuraMatrix™ and supplemented with osteogenic induction media showed early extra-cellular matrix formation and mineralization in addition to increased osteogenicity. Furthermore, the functionalization of RADA16 with bone bioactive motifs enhanced cell attachment, proliferation and osteogenic differentiation in vitro. In animal studies, combination of the nano-material with other porous biomaterials (DBM) and growth factors (BMP-2, PRP) further enhanced the capacity of PuraMatrix™ for in vivo osteoblast growth and osteogenesis.
Conclusions: Although the number of studies identified in this review is limited; available/accruing evidence suggests PuraMatrix™ is a promising carrier/scaffold for stem cell based craniofacial bone tissue engineering. Additional studies are deemed necessary to assess safety, efficacy, impact potential and cost-effectiveness of this new technology on future regenerative Cranio-Maxillo-Facial fields.
Keywords: Hydrogel; Nano fiber; PuraMatrix; Bone; Stem Cells; Tissue Engineering
Abbreviation: ECM: Extracellular matrix; PM: PuraMatrix™; RCTs: Randomized clinical trials; BMMSC: Bone marrow mesenchymal stem cells; BIC: bone-to-implant contact; rh-BMP-2: Recombinant human bone morphogenetic protein 2; PRP: Platelet-rich plasma; PLGA: Polyglycolic-co-lactic acid; DBM: Demineralized allograft cancellous bone matrix
Healing of bone fractures and regeneration of critical-sized defects remains a challenge in contemporary Oral and Maxillo-Facial surgery. Use of auto-grafts is the “gold standard” choice in these cases; however several disadvantages associated with their use (i.e. limited donor supply, increased morbidity, lengthening of the surgical intervention, to list a few.) seriously limit their application [1-3]. Alternative allogeneic and xenogeneic “graft substitutes” offer solution to some of the a fore mentioned inconveniences, none the less increased risk of (a) anti genicity and (b) foreign body reactions reduce their biological performance, while (c) high-cost manufacture restricts their clinical application [1,4]. Despite various alternative biomaterials have been tested (i.e. beta-tricalcium phosphate, hydroxyapatite and polymers) a simple, inexpensive and universal scaffold for tissue regeneration is still not available [1-3]. Thus, the development of new alternative biomaterials for bone regeneration continues to be a hot research, development and innovation topic, especially in the field of Dentistry. On the other hand, self-assembly is a well-known phenomenon within nature, consisting of the spontaneous organization of molecules - under thermodynamic equilibrium conditions-; into highly organized and stable macromolecular entities with specific functions [5]. In connective tissues, self-assembling of collagen and other proteins (such as laminin and fibronectin) result in extracellular matrix (ECM) formation. Because of this and their capacity to form hydrogels, these proteins (especially collagen I) have been extensively used for the development of scaffolds for regeneration [5]. In the last decades, advances in cell biology and tissue-engineering allowed identification of key proteins involved in ECM self-assembling. The discovery enabled scientists to create “new generation peptides” for manufacturing simpler and customizable scaffolds for regeneration [5].
RAD16-I (commercially available as PuraMatrix™, BD Bioscience, Bedford, MA, USA) is one of such newly-designed peptides for tissue-engineering. The 16-amino-acid peptide (Figure 1) derives from and alternating sequence of hydrophilic and hydrophobic amino-acids [Arginine (R), Alanine (A) and aspartic acid (D)] which - under physiologically salt and pH conditions -organize in B-Sheet configuration forming insoluble membranes [5]. Compared to other 3-dimensional cell culture systems, PuraMatrix™ excels at mimicking the natural ECM as both its nano scale network and biomechanical properties are similar to those of collagen I [5]. The material is also “inert” or “non-intrusive” as absence of cytokines and growth factors allows cells to migrate, proliferate and interact in a permissive/natural environment composed exclusively of synthetic proteins and 99.5% water [5-7]. This not only makes PuraMatrix™ an ideal nano scaffold for in vitro cell study, then again opens the door for further functionalization of the matrix in order to fulfill individual culture requirements or functions; i.e. cell differentiation [5]. The aforementioned is of vital importance in the race for developing next generation biomaterials as XXI century scaffolds should have both, instructive and inductive capacity over cells [5,8]. Furthermore, the development of new strategies for bone regeneration requires not only new biomaterials, yet also an entire bioengineering platform which assists regeneration [5]. This platform should be (a) biocompatible and safe, (b) guarantee biomineralization;(c) allow functional osteoblast migration, proliferation and differentiation; (d) permit the establishment of an adequate vascularization network and (e) maintain the biophysical and biomechanical properties of the bone [5].
Figure 1: The RAD16-I (PuraMatrix™) molecular amino-acid sequence.
In this context, PuraMatrix™ is a naturally-appealing strategy for cranio-facial bone regeneration as it offers several advantages over conventional scaffolds (Figure 2): (a) it is a liquid/solution that may be easily and directly injected into bone defects [5], (b) as far as it is known, does not produce immune responses or reactions [5], (c) self-polymerizes rapidly under physiological conditions forming solid 3-dimensional nano fiber hydrogels which adopt the geometry of the defect [5], (d) allows cell and growth-factor encapsulation and delivery into target tissues [5,6], (e) supports cell adhesion, survival, migration and proliferation [5,6], (f) has a porous 3-dimensional structure which allows free cell-to-cell contact (unlike other encapsulation materials were cells are surrounded by the matrix and must digest it in order to interact and migrate) [6] and (g) may be easily functionalized in order to meet individual needs of the target site [5]. An example of this would be the possibility to modify PuraMatrix™ in order to include bioactive motifs for biomineralization to promote calcium hydroxyapatite crystal nucleation and development [5].
Figure 2: Electron micrograph of PuraMatrix™ peptide hydrogel and main characteristics as a bio-scaffold.
Indeed, studies suggest that PuraMatrix™ is a promising scaffold for stem cell-based engineering of mineralized dental tissues [19]. Studies regarding its application on bone tissue engineering report Mesenchymal Stem Cells (MSCs) and osteoblasts seeded in the scaffold survive, proliferate and successfully differentiate into osteogenic linage [9,10]. Combination with other porous biomaterials and peptides (such as poly-HIPE polymer and P24 peptide) further enhanced PuraMatrix™’ s capacity for in vivo osteoblast growth and osteogenesis, suggesting potential use/application for bone tissue engineering is genuine [5,10,11]. Hence, the purpose of this article is to provide an up-to-date overview on the application of PuraMatrix™ during craniofacial bone tissue engineering.
Materials and Methods
A structured literature search (Figure 3) was performed on PUBMED (May - July 2015) using MESH search terms “PuraMatrix” and “Bone” according to the following search strategy: “PuraMatrix [all fields] AND “Bone” [all fields]”. Results were limited by: seniority (5 years since publication), language (English) and full text availability. A total of 29 articles were found. Focus was centered on the use/application of self-assembling peptide hydrogel PuraMatrix™ in Bone Regeneration; reason why a total of 15articles (related to regeneration of other tissues) were excluded from this review. Four out of remaining 14 studies were also excluded because of no “full text” availability. Data from remaining articles was abstracted and compiled in tables for latter appraised by authors. Decision to exclude one more article was taken during this stage after authors realized the article used RADA-P24 (JI’ER Biotechnology Co. LTd., Shanghai, China) instead of PuraMatrix™ (BD Bioscience, Bedford, MA). It is noteworthy additional manual search on PuraMatrix™’s official web-page ( was performed to fetch for published or unpublished data. Despite finding 9 articles, none was added to this review as 5 publications were repeated and 4 were not available in Full-text format. In the same context, additional manual search on ( was performed in order to fetch finished or ongoing human randomized controlled clinical trials (RCTs); however no results were found. Results and methodology flow diagram are reported according to the “PRISMA STATEMENT” (
Figure 3: Flow-chart of performed systematic review methodology and reported findings/studies.
Results and Discussion
In total, 7 studies dealing with potential use and application of PuraMatrix™ in bone tissue engineering were found (3 in vitro studies and 4 animal trials - for more details please refer to Table 1 and Table 2, respectively). It is noteworthy that no RCTs were found; signifying that this particular topic and biomaterial is a novel field of research and development within bone regeneration and tissue engineering fields.
(MESH Definition)
Cell Line Scaffolds Follow-up Results Ref.
(Adherence of cells to surfaces or to other cells)
Control (RADA16, ALK, DGR, PRG)
14 d Cell attachment significantly higher in DGR- and PRG- RADA16 scaffolds vs. RADA16 controls. [8]
(Continuance of life or existence especially under adverse conditions)
N/A Seeded cells remained viable within scaffolds (MMT assay).  BMMSC appeared completely surrounded and encapsulated in PM™. [16]
human BMMSC 0.25% PM™
2D culture
21 d Cells retained normal fibroblast-like morphology within PM™ until osteogenic induction was made. [12]
  Cells retained normal fibroblast-like morphology. [13]
(Processes involved in increasing cell number including cell division).
human BMMSC 0.25% PM™ 2D culture 21 d Obvious proliferation was seen only on undifferentiated BMMSC.
No differences in cell proliferation rates in PM™ and control groups were noticed.
  MC3T3E1 RADA16 / ALK
Control (RADA16, ALK, DGR, PRG)
14 d Significant increase in cell proliferation in RADA16/DGR and RADA16/PRG vs. RADA16 control. [8]
Migration human BMMSC 0.25% PM™
2D culture
21 d Cells migrated successfully into PM™.  [12]
  HMS0014 1% PM™
2D culture
14 d Cells migrated freely within PM™. Appearance of cell processes extending into the matrix was noticed since 3 days of culture. [14]
  MC3T3E1 RADA16 / ALK
Control (RADA16, ALK, DGR, PRG)
14 d Cells migrated freely within PM™. Appearance of cell processes extending into the matrix was noticed. [8]
14 d Cells migrated into PM™ [13]
Differentiation human BMMSC 0.25% PM™
2D culture
21 d Once differentiated, cells changed from fibroblast- to osteoblast-like shape and formed small cell clusters.
Early ECM production and mineral nodule formation was reported in PM™ (7 day vs. 14 days in control).
Mineralization sites within PM™ located in and around osteoblast clusters
Non-induced PM™ cultures also showed some mineral deposition (positive Von Kossa staining)
No intergroup differences in BMP-2, RunX and OP gene-expression were noticed.
14 d Early ECM production and mineral nodule formation was reported in PM™ vs. control [13]
  HMS0014 1% PM™
2D culture
14 d PM™ group exhibited active osteogenic differentiation.
Increased ALP activity (P<0.01), Calcium volume (P<0.05) and Osteocalcin volume (P<0.01) were noticed on experimental group.
Calcium and Osteocalcin volume was 2x and 4x times higher than control.
  MC3T3E1 RADA16 / ALK
Control (RADA16, ALK, DGR, PRG)
14 d RADA16/DGR and RADA16/PRG showed significantly higher ALP activity and staining than RADA16 control.
Osteocalcine volume in all modified RADA16 scaffolds was higher than RADA 16 control.
RADA16/PRG showed the highest osteocalcine concentration among modified scaffolds (P<0.05) 
Table 1: In vitro findings on prospective use/application of PuraMatrix™ for Bone Tissue Engineering.
Application and Model
(Bone Defect dimensions)
Species Groups Follow-up Results Ref.
Implant Osseo-integration & Implants placed on  previously grafted alveolar sockets (10mm height x 10mm diameter) Dog
PM PM / dog BMMSC PM / dog BMMSC / PRP Control (defect only) 8, 16 w Bone formation
Control and PM groups exhibited cavities invaded by fibrous tissue.
PM/dog BMMSC showed partial bone formation.
PM/dog BMMSC/PRP showed mature bone formation.
PM/dog BMMSC and PM/dog BMMSC/PRP exhibited greater new-bone volume than PM and controls (significance not reported). BIC in PM group was 40.77% + 12.85%. PM/dog BMMSC showed 50.35% + 8.02% and PM/dog BMMSC/PRP exhibited 55.64% + 4.97%. BIC in Control groups was 30.57% + 2.50%.
PM/dog BMMSC BIC was significantly greater than control (P<0.05)
PM/dog BMMSC/PRP BIC was significantly greater than control and PM (P<0.01)
No significant differences were noticed between (a) PM and control and (b) PM/dog BMMSC and PM/dog BMMSC/PRP
Periodontal Regeneration & King and Hughes' Periodontal wound model (18). (2mm height x 2mm depth x 3-4mm width) Rat
Human BMMSC / PM / HELISTAT (Collagen sponge, Integra Life Sciences corp.) PM / HELISTAT Control (defect only) 1, 4 w All animals survived. No adverse reactions were noticed. Cell viability in vivo
Human DNA was detected only were hBMMSC were implanted. Cells were located mainly in the periodontal defect. hBMMSC numbers decreased significantly over time. No cells were detected at 4 w (PCR method). Bone Formation
At 1w, control group defects were filled with loose-connective tissue. No new bone formation was found in any of the other samples. At 4w, newly formed bone was found in all samples. Partial regeneration of damaged periodontal ligament and cement was noticed. No significant differences between treated groups were found regarding (a) the amount of newly formed bone and (b) the healing of periodontal ligament and cementum. Damaged dentin did not heal. Bone volume density was significantly higher in hBMMSC vs. non-hBMMSC groups only at 1w. Osteoclast numbers were significantly reduced in hBMMSC treated group vs. control at 1 and 4w. No osteoclasts were found in healthy controls (no defect).
Bone Regeneration & Calvarial defect under titanium dome. (6mm diameter x 1mm depth) Rabbit
PM rhBMP-2 / saline PM / rhBMP-2 Control (Defect only) 8 w All animals survived. Newly formed bone was seen in all groups. Maximum height of newly formed bone in PM/rhBMP-2 was significantly higher than control (P<0.01) and rhBMP-2 or PM alone (P<0.05). Area of newly formed bone in PM/rhBMP-2was significantly higher than control (P<0.05) Average regenerated tissue in control was 35.8 + 10.35%.  PM and rhBMP-2 exhibited 48.94 + 11.33% and 47.94 + 5.65% respectively. PM/rhBMP-2 showed 58.06 + 14.84% and was significantly higher than control (P<0.05). [15]
Bone Regeneration & Femoral defect (20mm depth x unknown) Goat
8, 16 w All animals survived. PM formed a 3-dimensional interlacing network in the inner wall of DBM. Bone Formation
At 8 w, all animals experienced some new bone formation however, no union occurred. PM treated group showed massive osteoid formation, whereas control exhibited cartilage-like tissues with less osteoid.
At 16 w, bone union occurred in all samples. PM-enriched group was completely reconstructed while control was partially regenerated. PM treated group exhibited extensive lamellar bone while control had abundance of woven bone. Volume of new bone was significantly higher in the PM group vs. control (P<0.05). Mean Bone Density was significantly higher in PM/DBM/goat BMMSCS group vs. control at 16 w(P<0.05), however no difference was found at 8 w.
Table 2: In vivo studies evaluating prospective use/application of PuraMatrix™ for Bone Tissue Regeneration.
In vitro Studies
PuraMatrix™ supports in vitro survival, proliferation and migration of osteoblast-like cells
Undifferentiated BMMSC seeded within PM™ retained fibroblast morphology as they migrated within the scaffold [13]. Once inside, cells remained viable and developed multiple “processes” extending into the matrix and other cells [12]. Aforementioned protrusions are typical in cells cultured on 3-dimensional culture systems and are thought to participate in communication through direct cell-to-cell contact. Iwai et al.(who also reported the appearance of these protrusions) described the phenomenon to occur as early as 3 days into PuraMatrix™ culture [14]. Regarding cell proliferation, Chen et al.reported only undifferentiated BMMSC proliferated within the matrix [12]. This is within the expected as differentiation to osteoblasts (terminal-line cells) reduce mitogenesis and cell division. Finally, PuraMatrix™ did not interfere with BMMSC proliferation as no differences regarding this parameter were noticed when comparing cells seeded onto 2D-culture system and the nanofibrous scaffold [12].
PuraMatrix™ supports in vitro osteogenic differentiation of osteoblast-like cells
During osteogenic induction, BMMSC cells underwent dramatic morphology changes shifting from fiboblast-like-toosteoblast form [12]. Cell distribution was also altered as osteoblasts grouped into small clusters whereas undifferentiated BMMSC remained isolated within the matrix [12]. ECM production and mineralization (measured by ECM secretion and mineral nodule formation) was noticed earlier in induced PM™ cultures (day 7) vs. 2D-controls (day 14) [12,14]. Interestingly, non-induced PM™ cultures also showed some mineral deposition (measured by positive Von Kossa staining) [12]. Slight osteogenic differentiation of these particular cultures despite absence of osteoinductive media or any other extrinsic osteogenic growth factor suggest PM™’s architecture may positively influence BMMSC differentiation none the less, more studies are needed in order to test this hypothesis. Calcium X-ray density analyses of induced PM™ cultures revealed mineralization nodules occurred at specific localizations within the nano-scaffold. Further analysis using X-ray intensity maps evidenced most calcium deposits appeared in and/ or around osteoblast clusters [12]. Complementary analyses of oteogenic marker gene-expression during culture induction showed no differences between PM™ and 2D cultures regarding the expression of BMP-2, Runx2 and OP [12]. A second study by Iwai et al.studied HMS0014 cells cultured on PM™ [14]. In his study, cells were seeded into 1% PM™ and then cultured for 14 days under: (a) normal or (b) osteogenic induction conditions. Results from this study are similar to those reported for BMMSC, indicating survival and active osteogenic differentiation occurred under osteogenic induction. HMS0014 on induced-PM™ showed increased ALP activity (P<0.01) and nearly 2x- and 4x times higher Calcium (P<0.05) and Osteocalcin (P<0.01) volumes than 2D induced controls [14].
Functionalized PuraMatrix™ increases biocompatibility and osteogenicity
As it was previously mentioned, PM™ may be further customized in order to fulfill specific functions. In Horiiet al.’sstudy, RAD16-Iwas functionalized adding one of the following three bioactive motifs: (a) Osteogenic growth factor peptide (ALK), (b) Osteopontin cell adhesion motif (DGR) or (c) specially designed 2-unit binding sequence (PRG). Biocompatibility and osteogenicity of these “second generation” scaffolds was tested in vitro using MC3T3-E1 cells [8]. After 2 weeks of continuous culture, MC3T3-E1’s attachment and proliferation was significantly improved in DGR- and PRG-modified scaffolds [8]. Cell attachment increase was within the expected as both motifs (DGR and PRG) contain well-documented RGD cell attachment sequences. Interestingly, it was also reported PRG concentrations as low as 1% may be sufficient for effectively increase cell adhesion and migration of MC3T3-E1 cells on RAD16-I, proving even minor modifications to PM™’s sequence may dramatically improve its in vitro/in vivo performance. Regarding osteogenicity, Horii et al. Reported ALK- and PRG-modified RAD16-I scaffolds presented significantly higher osteogenic potential (measured by ALP activity and staining) than non-functionalized controls [8]. Osteocalcin volume concentration (a late osteogenic biomarker) was also significantly increased in all modified scaffolds, among which PRG-modified RADA16 showed the highest concentration [8].
Collectively, the aforementioned analysis suggests that the functionalization of PuraMatrix™ seems to be a simple, effective and inexpensive strategy (or at least less than polymer or natural collagen functionalization) to create customized/improved “second generation scaffolds”withosteoconductive and osteoinductive properties suitable for bone tissue engineering.
Pre-clinical Animal (in vivo) Studies
Pre-clinical models found on this review (Table 2) evaluated the prospective use of PuraMatrix™ for bone tissue engineering using four different animal species (dog, rat, rabbit and goat) and two models: (a) treatment of critical-sized bone defects (Calvarial [15], Femoral [13]and Periodontal [16]) and (b) implant osseointegration [17]. Outcomes as well as defect type, location and size were not uniform; hence results are presented in narrative format. Since the scaffold is composed solely by peptides and water, osteogenicity was achieved using the following strategies: (a) combination with Bone Marrow Mesenchymal stem cells [13,16,17], (c) combination with growth factors (rhBMP-2 [15] and PRP [17]) and/or (d) mixing with other biomaterials (collagen membrane HELISTAT [16] or DBM [13]). Main source of mesenchymal stem cells were same species animals, with exception of Tcacencu’s study [16] in which human BMMSCs were used with no adverse effects.
PuraMatrix™ in the treatment of critically-sized bone defects
PuraMatrix™ in large bone defects:
Treatment of trans-segmental femoral defects using P™-modified DBM grafts was addressed by Li., et al. [13]. This particular model has been extensively used in the literature as a challenging environment for testing bone grafts in outsized defects; hence it was also used as a way to test PM™’s potential in large bone defects. Rationale behind PM™ and DBM combination came from the evidence reporting that the loss of chemical and physical reconstituents during DBM production often led to gross pore size (200-900um) and low in vitro adhesiveness of cells and growth-factors. Thus, addition of PM™ was thought as a way to increase osteo progenitor cell adhesion and migration within DBM grafts. This is plausible as PM™ forms 3-dimensional nano scale networks (10nm fibers and 2-300 nm pores) within several micro scale scaffolds [10,13]. In Li’s study, critically-sized defects on the mid-diaphyses of goat femurs were treated using (a) BMMSC/DBM or (b)PM™/BMMSC/DBM construct [13]. Quantitative assessment of new bone formation was made at 8 and 16 weeks post-surgery by means of histologic- and radiological analysis. It must be noticed authors reported uneventful healing in all animals and no adverse reactions to the biomaterials. Radiographic evaluation 8 weeks post-surgery revealed that both groups experienced partial bone union however, PM™-treated femurs exhibited evident and abundant cortical bone formation (unlike controls in which cortical bone was poorly seen) [13]. Histological analyses of the same samples revealed that massive osteoid formation had occurred in the PM™ group, whereas extensive cartilage-like tissues and minor osteoid was found in control lesions. Intergroup differences in new bone volume and density were non-significant at this stage. At 16 weeks, radiographic bone union was complete in both groups. Cortical bone on PM™ group appeared completely reconstructed whereas non-PM™ femurs still showed partial regeneration in one of their sides. Histological analyses revealed extensive lamellar bone in PM™-treated group whereas woven bone was still predominant on controls. Quantification of bone formation using radiological scores revealed de novo/new bone volume and density was significantly higher in the PM™ group [13].
Collectively, these findings suggest that the modification of DBM grafts with PuraMatrix™ may provide significant additional benefits on bone formation, maturation and remodelling. The aforementioned strategy appears as a simple and viable approach for enhanced and accelerated wound healing in large bone defect; and thus could be also applied in the treatment/regeneration of extensive maxillo-facial defects.
PuraMatrix™in craniofacial defects:
Ikeno., et al. evaluated use/application of rhBMP-2-enriched PM™ in the treatment of small craniofacial bone defects [15]. In their study, critically-sized calvarial defects on rabbits were treated with either: (a) PM™, (b) rhBMP-2 (25ug/mL) or (c) a combination of both. Untreated bone defects were used as negative controls [15]. After 8 weeks, animals were euthanized and ground sections were obtained for histomorphometric analysis. It must be noticed all animals experienced uneventful healing and no adverse effects to the therapy were reported. Study results showed newly formed bone in all groups however; the amount, height and area were significantly higher in the PM™/rhBMP-2 combined group vs. control (P<0.05) [15]. Osteogenic potential of the biomaterial on its own was lower than that of PM™/rhBMP-2 combination yet similar to that of rhBMP-2-alone; nonetheless despite how promising this may sound (since rhBMP-2 is highly osteoinductive); no significant differences with control were found [15]. An interesting thing about this study was the fact that used rhBMP-2 concentration was of at least 10 to 50 times lower than that of most experimental and clinical studies evaluating rhBMP-2 on bone regeneration [15]. On one hand, this could explain why the PM™- and rh-BMP-2-groups had similar results with no significant differences vs. control (maybe concentration was too low), however on the other and more interesting side, the fact that PM/rhBMP-2 group showed significant bone regeneration (despite low rhBMP-2 concentration) suggesting that PuraMatrix™ may be an effective delivery system for clinical application of rhBMP-2in craniofacial bone tissue engineering. According to authors, in vitro release kinetics for PM™/rhBMP-2 constructs were fast in the first two hours and then slower over time, until reaching plateau at 30 to 50 hours of application. Functional protein release was observed to occur for over a 2 to 3 week period [15]. The fore mentioned indicates that long term functionaldelivery of rhBMP-2 (in an appropriate time for bone regeneration to occur)is possible using PuraMatrix™. Additional benefits of this particular regeneration strategy include: (a) efficient reduction of the rhBMP-2effective dosestoclinically accepted concentrations, (b) increased safety for in vivo application and (c) user-friendly/malleable application in complex defects such as alveolar clefts, periodontal intra-bony defects, peri-implant defects, etc [15].
Tcacencu., et al. evaluated the use of human BMMSCs on PM™-modified HELISTAT collagen membranes for the treatment of periodontal intra-bony defects [16]. Defects were prepared using King and Hughes’s rat periodontal wound model [18]: extra-oral incisions at the lower mandible border were made. Both, fascia and masseter muscle were retracted to permit for direct access to the mandibular bone. Afterwards, all tissues overlying distal root of the first molars (bone, periodontal ligament, cementum and superficial dentine) were removed preserving tooth vitality. Defects were treated using the following strategies: (a) BMMSC/PM™/HELISTAT, (b) PM™/HELISTAT or (c) none (defect only) [16]; and flap was positioned using sutures. Quantitative assessment of new bone formation was made at 1 and 4 weeks post-surgery by means of histomorphometric analysis. Histological evaluation at 1 week post-surgery revealed all lesions remained unhealed. No new bone formation was found thus, defects were filled with loose connective tissue. At 4 weeks, all groups exhibited new bone formation and various degrees of periodontal ligament and cementum repair. No Dentin regeneration was observed. Intergroup differences on the wound healing rate were noticed. Quantitative assessment of bone tissue volume/density surrounding treated roots at 1 and 4 weeks revealed significant differences favouring both experimental groups over control. Intergroup comparison further indicated BMMSC/PM™/HELISTAT-treated lesions had significantly more bone than PM™/HELISTAT groups. It is worth mentioning here in that the absence of PM™- and HELISTAT-alone controls in Tcacencu’s study makes it difficult to determine the real potential and efficiency of PuraMatrix™ in periodontal bone regeneration. The reported results indicate that the PuraMatrix™/HELISTAT combination may enhance bone tissue regeneration, nonetheless whether this is an effect of the nano scaffold or its combination with HELISTAT, remains unknown.
PuraMatrix™ in implant osseo-integration
Potential effects of PuraMatrix™ on implant osseointegration were evaluated by Kogho., et al. [18]. In this study, post-extraction sockets in dogs were allowed to heal for 4 weeks before implants(Nobel BioCare) were placed using the following grafts: (a) PM™, (b) PM™/BMMSC, (c) PM™/BMMSC/PRP or (d) none (defect only). Eight weeks later, animals were euthanized and bone biopsies were taken in order to assess bone-to-implant contact (BIC) [18]. Macroscopic findings during biopsy revealed partial bone formation occurred in control, PM™ and PM™/BMMSC groups. Histological findings confirmed sockets were filled with either (a)fibrous tissues (control and PM™ -alone groups) or (b)partial/immature bone (PM™/BMMSC group) [18]. In contrast, complete macroscopic bone formation was seen on the PM™/BMMSCS/PRP group. Further histologic analysis of samples revealed extensive bone formation and maturation within this particular group [18]. Considering this, minimal implant thread exposure also reported for this group should not come as a surprise. Regarding Bone-to-implant contact (BIC), use of PM™-alone provided a slight non-significant increase in the BIC vs. control (40.77% + 12.85% vs. 30.57% + 2.50%respectively). When BMMSC were added to the scaffold, further and significant increase of BIC was noticed (50.35% + 8.02%) nonetheless it was only significant when comparing with control and not PM™-alone group. The PM™/BMMSC/PRP group exhibited the highest BIC value within the study (55.64% + 4.97%). Intergroup comparisons revealed the BIC in this group was significantly higher than those of control and PM™-alone groups[18].
Findings suggest that PuraMatrix™ may be useful for peri-implant bone regeneration and implant osseointegration when combined with BMMSC and (even more) BMMSC with growth-factor supplements (i.e. PRP). Clinical applicability as well as efficacy of this approach remain to be elucidated, as the model used in this study offers favorable conditions for bone regeneration/osseointegration, thus offering little to no challenge for adequately testing the true regenerative potential extent of PuraMatrix™ as the “ideal” bio scaffold.
Injectable biomaterials and hydrogels, particularly those delivered in aqueous formats, are considered ideal delivery/carrier vehicles for cells, drugs and bioactive growth factors. This is particularly true due to allowing to fill complex 3-D defects with minimal-invasiveness [19]. PuraMatrix™ is a synthetic, injectable and self-assembling peptide nanofibrous hydrogel scaffold recently introduced in the bone tissue engineering field. The nano-fiber scaffold supports osteoblast-like stem cell viability, proliferation and migration without interfering with cell osteogenic differentiation. Demonstrated in vitro functionalization of the RADA16 sequence with bone bioactive motifs (a simple, easy and inexpensive way to improve the biomaterial properties) as well as in vivo combination with other porous biomaterials and growth factors may further enhance osteogenesis while allowing the potential development of “second generation” nano-fiber scaffolds; specially tailored for osseo regeneration. Ability to form scaffolds or networks capable of both replacing tissue function early after delivery and supporting tissue regeneration over a time period of weeks to months, is highly attractive. Yet, the number of studies available to date is limited. Nonetheless, accruing evidence [20] suggests that PuraMatrix™ may be a promising hydrogel scaffold for cell-/protein-based cranio-facial bone tissue engineering. Future studies will explore the application of PuraMatrix™ (and its composites) and assess its safety, efficacy, impact and cost-effectiveness as a potential bioengineering strategy for clinical craniofacial regeneration, and beyond.
This work was supported by generous funding and operating grants provided to the BioMAT’X Research Group, partner of CIBRO (Centro Investigación en Biología y Regeneración Oral) and part of CIB (Centro de Investigación Biomédica), through the Faculty of Dentistry and PMI (Plan de Mejoramiento Institucional en Innovación I+D+i), Department for Research, Development and Innovation, Universidad de Los Andes, Santiago de Chile.
Conflict of Interest
Authors of this article declare having no conflict of interest. However, it is worth mentioning that the corresponding author has an ongoing partnership (via which PuraMatrix™ is obtained) with 3-D Matrix Medical Technology, Inc. - Europe SAS, Caluire, France, a subsidiary of 3-D Matrix, Ltd., Tokyo, Japan, where a family of peptide biomaterials is developed and manufactured for use in clinical applications and life science research.
  1. Giannoudis P., et al. “Bone substitutes: An update”. Injury 36.3 (2005): S20-S27.
  2. Habibovic P., et al. “Osteoinductive biomaterials-properties and relevance in bone repair”. Journal of Tissue Engineering and Regenerative Medicine 1.1 (2007): 25-32.
  3. Hallman M., et al. “Bone substitutes and growth factors as an alternative/complement to autogenous bone for grafting in implant dentistry”. Periodontology 2000 47.1 (2008): 172-192.
  4. Anderson J., et al. “Foreign body reaction to biomaterials”. Seminars in Immunology 20.2 (2008): 86-100.
  5. Semino C. “Self-assembling peptides: from bio-inspired materials to bone regeneration”. Journal of Dental Research 87.7 (2008): 606-616.
  6. Cuddihy M., et al. “Replication of Bone Marrow Differentiation Niche: Comparative Evaluation of Different Three-Dimensional Matrices”. Small 9.7 (2013): 1008-1015.
  7. Biosciences BD. “BDTM PuraMatrixTM Peptide Hydrogel”.
  8. Horii A., et al. “Biological Designer Self-Assembling Peptide Nanofiber Scaffolds Significantly Enhance Osteoblast Proliferation, Differentiation and 3-D Migration”. PLoS ONE 7.2 (2007): e190.
  9. Yoshimi R., et al. “Self-assembling peptide nanofiber scaffolds, platelet-rich plasma, and mesenchymal stem cells for injectable bone regeneration with tissue engineering”. Journal of Craniofacial Surgery 20.5 (2009): 1523-1530.
  10. Bokhari M., et al. “The enhancement of osteoblast growth and differentiation in vitro on a peptide hydrogel-polyHIPE polymer hybrid material”. Biomaterials 26.25 (2005): 5198-5208.
  11. Pan H., et al. “Bone induction by biomimetic PLGA copolymer loaded with a novel synthetic RADA16-P24 peptide in vivo”. Materials Science and Engineering 33.6 (2013): 3336-3345.
  12. Chen J., et al. “Enhanced Osteogenesis of Human Mesenchymal Stem Cells by Periodic Heat Shock in Self-Assembling Peptide Hydrogel”. Tissue Engineering Part A 19.5 (2013): 716-728.
  13. Li Z., et al. “Bone marrow enriched graft, modified by self-assembly peptide, repairs critically-sized femur defects in goats”. International Orthopaedics 38.11 (2014): 2391-2398.
  14. Iwai Y., et al. “A preliminary study of the dental implant therapy-initial osteogenesis of Human Mesenchymal Stem (HMS0014) cells on titanium discs with different surface modifications”. Okajimas Folia Anatomica Japonica 88.4 (2012): 88.4:133-140.
  15. Ikeno M., et al. “Effects of Self-Assembling Peptide Hydrogel Scaffold on Bone Regeneration with Recombinant Human Bone Morphogenetic Protein-2”. The International Journal of Oral & Maxillofacial Implants 28.5 (2013): e283-e289.
  16. Tcacencu I., et al. “Transplanted Human Bone Marrow Mesenchymal Stem Cells Seeded onto Peptide Hydrogel Decrease Alveolar Bone Loss”. BioResearch Open Access 1.5 (2012): 215-221.
  17. Kohgo T., et al. “Bone regeneration with self-assembling peptide nanofiber scaffolds in tissue engineering for osseointegration of dental implants”. International Journal of Periodontics & Restorative Dentistry 31.4 (2011): e9-e16.
  18. King G., et al. “Bone morphogenetic protein-2 stimulates cell recruitment and cementogenesis during early wound healing”. Journal of Clinical Periodontology 28.5 (2001): 465-475.
  19. Haidar ZS., et al. “Bio-Inspired/-Functional Colloidal Core-Shell Polymeric-Based NanoSystems: Technology Promise in Tissue Engineering, Bioimaging and NanoMedicine”. Polymers 2.3 (2010): 323-352.
  20. Haidar ZS., et al. “Self-Assembling Peptide Nano fibrous Scaffold (PuraMatrix™) in Regenerative Endodontics”. EC Dental Science 2.5 (2015): 394-402.
Copyright: © 2016 Ziyad S Haidar., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

PubMed Indexed Article

EC Pharmacology and Toxicology
LC-UV-MS and MS/MS Characterize Glutathione Reactivity with Different Isomers (2,2' and 2,4' vs. 4,4') of Methylene Diphenyl-Diisocyanate.

PMID: 31143884 [PubMed]

PMCID: PMC6536005

EC Pharmacology and Toxicology
Alzheimer's Pathogenesis, Metal-Mediated Redox Stress, and Potential Nanotheranostics.

PMID: 31565701 [PubMed]

PMCID: PMC6764777

EC Neurology
Differences in Rate of Cognitive Decline and Caregiver Burden between Alzheimer's Disease and Vascular Dementia: a Retrospective Study.

PMID: 27747317 [PubMed]

PMCID: PMC5065347

EC Pharmacology and Toxicology
Will Blockchain Technology Transform Healthcare and Biomedical Sciences?

PMID: 31460519 [PubMed]

PMCID: PMC6711478

EC Pharmacology and Toxicology
Is it a Prime Time for AI-powered Virtual Drug Screening?

PMID: 30215059 [PubMed]

PMCID: PMC6133253

EC Psychology and Psychiatry
Analysis of Evidence for the Combination of Pro-dopamine Regulator (KB220PAM) and Naltrexone to Prevent Opioid Use Disorder Relapse.

PMID: 30417173 [PubMed]

PMCID: PMC6226033

EC Anaesthesia
Arrest Under Anesthesia - What was the Culprit? A Case Report.

PMID: 30264037 [PubMed]

PMCID: PMC6155992

EC Orthopaedics
Distraction Implantation. A New Technique in Total Joint Arthroplasty and Direct Skeletal Attachment.

PMID: 30198026 [PubMed]

PMCID: PMC6124505

EC Pulmonology and Respiratory Medicine
Prevalence and factors associated with self-reported chronic obstructive pulmonary disease among adults aged 40-79: the National Health and Nutrition Examination Survey (NHANES) 2007-2012.

PMID: 30294723 [PubMed]

PMCID: PMC6169793

EC Dental Science
Important Dental Fiber-Reinforced Composite Molding Compound Breakthroughs

PMID: 29285526 [PubMed]

PMCID: PMC5743211

EC Microbiology
Prevalence of Intestinal Parasites Among HIV Infected and HIV Uninfected Patients Treated at the 1o De Maio Health Centre in Maputo, Mozambique

PMID: 29911204 [PubMed]

PMCID: PMC5999047

EC Microbiology
Macrophages and the Viral Dissemination Super Highway

PMID: 26949751 [PubMed]

PMCID: PMC4774560

EC Microbiology
The Microbiome, Antibiotics, and Health of the Pediatric Population.

PMID: 27390782 [PubMed]

PMCID: PMC4933318

EC Microbiology
Reactive Oxygen Species in HIV Infection

PMID: 28580453 [PubMed]

PMCID: PMC5450819

EC Microbiology
A Review of the CD4 T Cell Contribution to Lung Infection, Inflammation and Repair with a Focus on Wheeze and Asthma in the Pediatric Population

PMID: 26280024 [PubMed]

PMCID: PMC4533840

EC Neurology
Identifying Key Symptoms Differentiating Myalgic Encephalomyelitis and Chronic Fatigue Syndrome from Multiple Sclerosis

PMID: 28066845 [PubMed]

PMCID: PMC5214344

EC Pharmacology and Toxicology
Paradigm Shift is the Normal State of Pharmacology

PMID: 28936490 [PubMed]

PMCID: PMC5604476

EC Neurology
Examining those Meeting IOM Criteria Versus IOM Plus Fibromyalgia

PMID: 28713879 [PubMed]

PMCID: PMC5510658

EC Neurology
Unilateral Frontosphenoid Craniosynostosis: Case Report and a Review of the Literature

PMID: 28133641 [PubMed]

PMCID: PMC5267489

EC Ophthalmology
OCT-Angiography for Non-Invasive Monitoring of Neuronal and Vascular Structure in Mouse Retina: Implication for Characterization of Retinal Neurovascular Coupling

PMID: 29333536 [PubMed]

PMCID: PMC5766278

EC Neurology
Longer Duration of Downslope Treadmill Walking Induces Depression of H-Reflexes Measured during Standing and Walking.

PMID: 31032493 [PubMed]

PMCID: PMC6483108

EC Microbiology
Onchocerciasis in Mozambique: An Unknown Condition for Health Professionals.

PMID: 30957099 [PubMed]

PMCID: PMC6448571

EC Nutrition
Food Insecurity among Households with and without Podoconiosis in East and West Gojjam, Ethiopia.

PMID: 30101228 [PubMed]

PMCID: PMC6086333

EC Ophthalmology
REVIEW. +2 to +3 D. Reading Glasses to Prevent Myopia.

PMID: 31080964 [PubMed]

PMCID: PMC6508883

EC Gynaecology
Biomechanical Mapping of the Female Pelvic Floor: Uterine Prolapse Versus Normal Conditions.

PMID: 31093608 [PubMed]

PMCID: PMC6513001

EC Dental Science
Fiber-Reinforced Composites: A Breakthrough in Practical Clinical Applications with Advanced Wear Resistance for Dental Materials.

PMID: 31552397 [PubMed]

PMCID: PMC6758937

EC Microbiology
Neurocysticercosis in Child Bearing Women: An Overlooked Condition in Mozambique and a Potentially Missed Diagnosis in Women Presenting with Eclampsia.

PMID: 31681909 [PubMed]

PMCID: PMC6824723

EC Microbiology
Molecular Detection of Leptospira spp. in Rodents Trapped in the Mozambique Island City, Nampula Province, Mozambique.

PMID: 31681910 [PubMed]

PMCID: PMC6824726

EC Neurology
Endoplasmic Reticulum-Mitochondrial Cross-Talk in Neurodegenerative and Eye Diseases.

PMID: 31528859 [PubMed]

PMCID: PMC6746603

EC Psychology and Psychiatry
Can Chronic Consumption of Caffeine by Increasing D2/D3 Receptors Offer Benefit to Carriers of the DRD2 A1 Allele in Cocaine Abuse?

PMID: 31276119 [PubMed]

PMCID: PMC6604646

EC Anaesthesia
Real Time Locating Systems and sustainability of Perioperative Efficiency of Anesthesiologists.

PMID: 31406965 [PubMed]

PMCID: PMC6690616

EC Pharmacology and Toxicology
A Pilot STEM Curriculum Designed to Teach High School Students Concepts in Biochemical Engineering and Pharmacology.

PMID: 31517314 [PubMed]

PMCID: PMC6741290

EC Pharmacology and Toxicology
Toxic Mechanisms Underlying Motor Activity Changes Induced by a Mixture of Lead, Arsenic and Manganese.

PMID: 31633124 [PubMed]

PMCID: PMC6800226

EC Neurology
Research Volunteers' Attitudes Toward Chronic Fatigue Syndrome and Myalgic Encephalomyelitis.

PMID: 29662969 [PubMed]

PMCID: PMC5898812

EC Pharmacology and Toxicology
Hyperbaric Oxygen Therapy for Alzheimer's Disease.

PMID: 30215058 [PubMed]

PMCID: PMC6133268

News and Events

August Issue Release

We always feel pleasure to share our updates with you all. Here, notifying you that we have successfully released the August issue of respective journals and can be viewed in the current issue pages.

Submission Deadline for September Issue

Ecronicon delightfully welcomes all the authors around the globe for effective collaboration with an article submission for the September issue of respective journals. Submissions are accepted on/before August 21, 2020.

Certificate of Publication

Ecronicon honors with a "Publication Certificate" to the corresponding author by including the names of co-authors as a token of appreciation for publishing the work with our respective journals.

Best Article of the Issue

Editors of respective journals will always be very much interested in electing one Best Article after each issue release. The authors of the selected article will be honored with a "Best Article of the Issue" certificate.

Certifying for Review

Ecronicon certifies the Editors for their first review done towards the assigned article of the respective journals.

Latest Articles

The latest articles will be updated immediately on the articles in press page of the respective journals.

Immediate Assistance

The prime motto of this team is to clarify all the queries without any delay or hesitation to avoid the inconvenience. For immediate assistance on your queries please don't hesitate to drop an email to